Valneva–Leucadia: investor conference, 202111 supply service Valneva presents at Jefferies 2021 London Healthcare Conference

	Period	2021-11-16 ï¿½ 2021-11-17
	Region	London, Greater London
	Country	United Kingdom (GB)
	Partner, 1st	Valneva S.E. (Nasdaq: VALN, Euronext Paris: VLA)
	Group	Valneva (Group)
	Partner, 2nd	Jefferies International Ltd.
	Group	Leucadia (Group)
	Product	Jefferies 2021 London Healthcare Conference London + DIGITAL
	Person	Lingelbach, Thomas (Intercell 201106– CEO before COO before 2001– Chiron Behring)
	Person 2	Lawrence, David (Valneva 201708– CFO before Acambis + Chiron Vaccines + GSK)

Valneva S.E.. (11/8/21). "Press Release: Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference". Saint-Herblain.

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at the Jefferies London Healthcare Conference on November 16 and 17, 2021.

Valneva’s Chief Executive Officer Thomas Lingelbach and acting Chief Financial Officer David Lawrence will notably discuss the Company’s late stage vaccine candidates against Lyme disease (VLA15), chikungunya (VLA1553) and COVID-19 (VLA2001).

Valneva recently reported positive Phase 3 results for VLA2001[1], currently the only whole virus, inactivated, adjuvanted vaccine candidate against COVID-19 in clinical trials in Europe. The Company also announced last week the closing of a $102.0 million Global Offering[2].

Valneva’s presentation will take place on November 16, 2021 at 4:20pm GMT and can be accessed via the following link: https://wsw.com/webcast/jeff201/vla.pa/2050524. To request a meeting at the event, please contact your representative at Jefferies.

About Valneva SE

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.

Valneva Investor and Media Contacts

Laetitia Bachelot-Fontaine
VP, Global Communications and European Investor Relations
M +33 (0)6 4516 7099
investors@valneva.com

Joshua Drumm, Ph.D.
VP, Global Investor Relations
M +001 917 815 4520
joshua.drumm@valneva.com

[1] Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001

[2] Valneva Announces Closing of Approximately $102.0 Million Global Offering